Separate terms with OR to return results that match either term.
 
Clear All

9,635 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
68001-0480-22 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68001-0480-35 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68083-0381-01 68083-0381 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
68382-0913-06 68382-0913 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0913-16 68382-0913 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0913-84 68382-0913 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0914-06 68382-0914 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0914-16 68382-0914 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0914-84 68382-0914 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0915-06 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0915-16 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0915-84 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70700-0169-22 70700-0169 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70771-1521-03 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1521-07 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1521-09 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-03 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-07 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-09 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-03 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-07 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-09 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68001-0487-06 68001-0487 CAPECITABINE CAPECITABINE 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
42388-0023-26 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral April 25, 2016 In Use
42388-0023-36 42388-0023 Cabozantinib CABOMETYX 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 16, 2017 In Use

Found 9,635 results in 3 millisecondsExport these results